SRR1516087
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.390
- NOTCH_SIGNALING+0.190
- PI3K_AKT_MTOR_SIGNALING+0.190
- PROTEIN_SECRETION+0.140
- UNFOLDED_PROTEIN_RESPONSE+0.120
- UV_RESPONSE_DN+0.110
- PEROXISOME+0.080
- WNT_BETA_CATENIN_SIGNALING+0.080
- ADIPOGENESIS+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- ANGIOGENESIS-0.470
- E2F_TARGETS-0.460
- KRAS_SIGNALING_UP-0.380
- G2M_CHECKPOINT-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- ALLOGRAFT_REJECTION-0.360
- COAGULATION-0.350
- IL2_STAT5_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202456 | — | — | 0.859 |
| 2 | DRR168564 | — | — | 0.816 |
| 3 | sclc283559_S82.txt | — | cohortSC | 0.782 |
| 4 | SRR23303762 | — | — | 0.765 |
| 5 | SRR6013584 | — | cohortA1 | 0.753 |
| 6 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.752 |
| 7 | SRR23303776 | — | — | 0.750 |
| 8 | MDT-AP-0329 | Med | Medulloblastoma | 0.746 |
| 9 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.743 |
| 10 | TCGA-E7-A5KF-01A-11R-A28M-07 | — | — | 0.742 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |